Novel Coronavirus Characteristic Cerebrovasculopathic Effects by Zandpazandi, Sara & Shahmohammadi, Mohamad Reza
Dear Editor, 
Coronavirus beta 2 started infecting people from china in 
fall 2019. It did not take a long time to spread worldwide 
and take many victims and cause many deaths.
As it is known, beta coronaviruses (SARS-Cov-2), which 
cause the severe acute respiratory syndrome, COVID-19 
pandemic, have developed neurological manifestations in 
addition to primary respiratory symptoms in a significant 
number of patients.1,2 The occurrence of anosmia and 
hyposmia is evidence of this claim. 
Stroke incidence of 0.9%-2% in especially young 
COVID-19 patients, is reported.2-5 The worst issue about 
this incidence is the high mortality rate despite even 
optimal treatment.6,7 Since the number of patients is as 
much as the World Health Organization (WHO) could 
declare the disease pandemic, it is important to review 
the pathophysiology in order to estimate the risk and 
guide the decision making. This letter aims to review the 
mechanism of virus pathophysiology and the following 
cerebrovascular presentations reported until now. 
SARS- CoV-2 virus blocks the angiotensinogen-
converting enzyme 2 (ACE2), which plays a critical 
role in the autoregulation of cerebral perfusion. It has 
also reported that it induces a hypercoagulable state 
(same as other flu viruses but with more mortality) and 
a hyperinflammatory response with cytokine storm 
characterization.8,9 Inhibiting ACE2, neuroinvasion, and 
neurovirulation, and hypercoagulopathy induction are 
the pathophysiologic characteristics of the COVID-19.10-16
In some patients, the cerebrovascular attack was noticed 
as the early manifestation with no severe presentations. 
The vascular occlusion had seen in both arterial and 
venous sides; most of them occurred in large vessels. 
There are unusual manifestations reported in recent 
studies that there are young patients without previous 
history or risk factors, represented acute ischemic stroke, 
sinus thrombosis, tandem occlusion (internal carotid 
artery and middle cerebral artery M1 occlusion), carotid 
T occlusions, M1 and A2 occlusion, central retinal artery 
occlusion.17 
The mean age of the patients was lower than historical 
non-COVID stroke patients. There was a noticeable 
number of patients who presented the cerebrovascular 
stroke as the early manifestation of COVID-19. There 
is a report of a 9-day lag period between the COVID-19 
symptoms and the cerebrovascular event occurrence.16 
There are a few interpretations for the mechanism of 
COVID-19 vasculopathy incidence: epitheliopathy, i.e., 
a direct vasculopathic effect, immune-mediated platelet 
activation, potentiation of prothrombic surrounding, 
cardiac arrhythmias caused by infection, and also 
dehydration.12-15,18
It is vital in pandemic break-outs to raise awareness 
to improve decision-making, risk estimation, and health 
care workers’ protection. We should watch patients 
and novel manifestations precisely and report the new 
findings orderly for this issue.
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